Oscar Health $OSCR isn’t just another insurer riding the ACA wave, it’s the rare healthcare company that finally proved the thesis: a full-stack tech platform + disciplined pricing + AI-native operations can deliver both hyper-growth and real profitability in one of the most
Oscar Health’s $OSCR Q2 underscores a transformative shift:
$4.88B revenue (+70% YoY), $362M net income, and 2.96M members (+46% YoY).
Record first-half profitability (>$1B net income / $1.1B earnings from operations), MLR at 79.2%, and a company-record-low 14.2% SG&A ratio
$NIO continues to compound operational strength:
July deliveries +71% YoY to 35,934 units; YTD +68% to 227k with cumulative volume now past 1.22 million.
Flagship ES8 & ES9 are setting pace in China’s premium BEV segment above RMB 400k–500k, Gen-5 battery-swap network has hit
XPeng $XPEV is right now in subwave (4) of wave III.
The wave (4) is deeper than normal and nearly reached the 0.618 Fibonacci. If everything unfolds perfectly, it should touch the 0.618 Fibonacci at $11.36 and begin with wave (5) afterwards.
The downside risk is to go lower.
I have two ways of thought right now!
1) I am a reasonable investor in 8-15 companies. With no company above 15% allocation.
2) $OSCR is again below $30. I need to add! (Oscar Health is nearly two thirds of my portfolio)
Nothing changed for $NIO, therefore I am just going to post the chart.
For the commentary please refer to the text in the previous tweet.
As always, this is not financial advice, do your own research!
$ZETA delivers its 20th consecutive beat-and-raise quarter:
Q2 revenue $443M (+44% YoY), crushing the midpoint by $23 M. Adjusted EBITDA $92M at a 20.7% margin — locking in the Rule of 64.
First positive GAAP net income in recent periods ($8M / $0.03 EPS).
Free cash flow
